Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Up 125.8% in June

Vigil Neuroscience, Inc. (NASDAQ:VIGL) was the recipient of a large increase in short interest in the month of June. As of June 30th, there was short interest totalling 2,150,000 shares, an increase of 125.8% from the June 15th total of 952,100 shares. Approximately 13.8% of the company’s shares are sold short. Based on an average trading volume of 493,400 shares, the short-interest ratio is presently 4.4 days.

Vigil Neuroscience Trading Up 5.0 %

NASDAQ VIGL traded up $0.21 during mid-day trading on Thursday, hitting $4.40. The company’s stock had a trading volume of 418,260 shares, compared to its average volume of 299,823. The company’s 50 day simple moving average is $3.73 and its 200 day simple moving average is $3.34. Vigil Neuroscience has a twelve month low of $2.47 and a twelve month high of $9.98. The firm has a market capitalization of $165.35 million, a price-to-earnings ratio of -2.08 and a beta of 2.00.

Vigil Neuroscience (NASDAQ:VIGL) last posted its earnings results on Tuesday, May 7th. The company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.10. As a group, research analysts forecast that Vigil Neuroscience will post -2.1 EPS for the current year.

Hedge Funds Weigh In On Vigil Neuroscience

An institutional investor recently bought a new position in Vigil Neuroscience stock. Strs Ohio bought a new stake in Vigil Neuroscience, Inc. (NASDAQ:VIGL) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 8,200 shares of the company’s stock, valued at approximately $27,000. Institutional investors own 83.64% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on VIGL shares. HC Wainwright restated a “buy” rating and set a $24.00 target price on shares of Vigil Neuroscience in a research report on Friday, June 28th. JMP Securities reiterated a “market outperform” rating and issued a $23.00 price objective on shares of Vigil Neuroscience in a research note on Thursday, April 18th. Finally, Wedbush reissued an “outperform” rating and set a $23.00 target price on shares of Vigil Neuroscience in a research note on Thursday.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.